COPD Exacerbations Reduced Substantially With Dupilumab, Phase 3 Data Shows
November 27th 2023The NOTUS trial was shown to have successfully achieved its primary endpoint, demonstrating the notable efficacy of dupilumab in reducing exacerbations by 34% versus placebo in individuals with moderate-to-severe COPD showing evidence of type 2 inflammation.
Race, Ethnicity Data in Screening Model Could Reduce Lung Cancer Screening Disparities
September 21st 2023The ‘life-years gained from screening–computed tomography’ lung cancer screening model is recommended by the American College of Chest Physicians for personalizing patients’ shared decision-making in screening for lung cancer.